PDX tumors largely retained clinical features of the original biopsy, including the hallmarks of SCLC, inactivation of TP53 and RB1. The significance of the few differences we did observe in genomic spectra of primary tumors and their derivative models remains to be elucidated. This evidence concerns the gene TP53 and small cell lung carcinoma.